Efficacy, Hematologic Effects and Dose of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts


Efficacy, Hematologic Effects and Dose of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Moshe Talpaz, MD (2/19/13)

Talpaz M et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50-100 x 109/L): A comparison to patients with normal or high starting platelet counts. Proc ASH 2012;Abstract 176.

Dr Talpaz is Alexander J Trotman Professor of Leukemia Research, Associate Director of Translational Research at UM Comprehensive Cancer Center, Associate Chief of the Division of Hematology/Oncology and Director of Hematologic Malignancies at the University of Michigan Medical Center in Ann Arbor, Michigan.